 
Novartis
[Skip to main content](#main-content)
[![Novartis Home](/themes/custom/nvs_arctic/logo.svg "Home")](/)
* ![Open](/themes/custom/nvs_arctic/patterns/images/icon-search.svg)
![Close](/themes/custom/nvs_arctic/patterns/images/icon-close.svg)
Search
section
GlobalDigitalESGMedia CenterCareers
## Language & Country Selector for Desktop
![language-selector-globe](/themes/custom/nvs_arctic/patterns/images/globe.svg)
[Global |
**en**](javascript:void(0))
## 
Choose Location
* [**International**](#international)
* [**Americas**](#americas)
* [**Asia Pacific**](#asia-pacific)
* [**Europe**](#europe)
* [**Middle East & Africa**](#middle-east-africa)
* [Global | **en**](https://www.novartis.com/)
* [Sandoz | **en**](https://www.sandoz.com)
* [Novartis Foundation | **en**](https://www.novartisfoundation.org)
* [Argentina | **es**](https://www.novartis.com.ar/)
* [Brazil | **pt**](https://www.novartis.com.br/)
* [Canada | **en**](https://www.novartis.ca/en/)
* [Canada | **fr**](https://www.novartis.ca/fr/)
* [Central America | **es**](https://www.cac.novartis.com/)
* [Colombia | **es**](https://www.novartis.com.co/)
* [Mexico | **es**](https://www.novartis.com.mx/)
* [United States | **en**](https://www.novartis.us/)
* [Venezuela | **es**](https://www.novartis.com.ve/)
* [Australia | **en**](https://www.novartis.com.au/)
* [Bangladesh | **en**](https://www.novartis.com.bd/)
* [Hong Kong S.A.R. | **zh**](https://www.novartis.com.hk/)
* [India | **en**](https://www.novartis.in/)
* [Indonesia | **en**](https://www.id.novartis.com/)
* [Japan | **ja**](https://www.novartis.co.jp/)
* [Korea | **ko**](https://www.novartis.co.kr/)
* [Mainland China | **zh**](https://www.novartis.com.cn/)
* [Malaysia | **en**](https://www.novartis.com/my-en)
* [Pakistan | **en**](https://www.novartis.com/pk-en)
* [Philippines | **en**](https://www.novartis.com/ph-en/)
* [Singapore | **en**](https://www.novartis.com.sg/)
* [Taiwan | **zh**](https://www.novartis.com.tw/)
* [Austria | **de**](https://www.novartis.at/)
* [Belgium | **fr**](https://www.novartis.be/fr/)
* [Belgium | **nl**](https://www.novartis.be/nl)
* [Bulgaria | **bg**](https://www.novartis.bg/)
* [Czech Republic | **cs**](https://www.novartis.cz/cs)
* [Czech Republic | **en**](https://www.novartis.cz/en)
* [Denmark | **da**](https://www.novartis.dk/)
* [Estonia | **et**](https://www.novartis.ee/)
* [Finland | **fi**](https://www.novartis.fi/)
* [France | **fr**](https://www.novartis.fr/)
* [Germany | **de**](https://www.novartis.de/)
* [Greece | **el**](https://www.novartis.gr/)
* [Hungary | **hu**](https://www.novartis.hu/)
* [Ireland | **en**](https://www.novartis.ie/)
* [Italy | **it**](https://www.novartis.it/)
* [Latvia | **lv**](https://www.novartis.lv/)
* [Lithuania | **lt**](https://www.novartis.lt/)
* [Netherlands | **nl**](https://www.novartis.nl/)
* [Norway | **no**](https://www.novartis.no/)
* [Poland | **pl**](https://www.novartis.pl/)
* [Portugal | **pt**](https://www.novartis.pt/)
* [Romania | **ro**](https://www.novartis.com.ro/)
* [Russia | **ru**](https://www.novartis.ru/)
* [Serbia | **sr**](https://www.novartis.rs/)
* [Slovakia | **sk**](https://www.novartis.sk/)
* [Spain | **es**](https://www.novartis.es/)
* [Sweden | **sv**](https://www.novartis.se/)
* [Switzerland | **de**](https://www.novartis.ch/de/)
* [Switzerland | **fr**](https://www.novartis.ch/fr/)
* [United Kingdom | **en**](https://www.novartis.co.uk/)
* [Egypt | **en**](https://www.novartis.com.eg/)
* [Israel | **he**](https://www.novartis.co.il/)
* [South Africa | **en**](https://www.novartis.co.za/)
* [Turkey | **tr**](https://www.novartis.com.tr/)
## Language & Country Selector for Mobile
![language-selector-globe](/themes/custom/nvs_arctic/patterns/images/globe.svg)
[Global](javascript:void(0))
### 
Choose Location
****international****
[International](#international)
[Americas](#americas)
[Asia Pacific](#asia-pacific)
[Europe](#europe)
[Middle East & Africa](#middle-east-africa)
* [Argentina | **es**](https://www.novartis.com.ar/)
* [Australia | **en**](https://www.novartis.com.au/)
* [Austria | **de**](https://www.novartis.at/)
* [Bangladesh | **en**](https://www.novartis.com.bd/)
* [Belgium | **fr**](https://www.novartis.be/fr/)
* [Belgium | **nl**](https://www.novartis.be/nl)
* [Brazil | **pt**](https://www.novartis.com.br/)
* [Bulgaria | **bg**](https://www.novartis.bg/)
* [Canada | **en**](https://www.novartis.ca/en/)
* [Canada | **fr**](https://www.novartis.ca/fr/)
* [Central America | **es**](https://www.cac.novartis.com/)
* [Colombia | **es**](https://www.novartis.com.co/)
* [Czech Republic | **cs**](https://www.novartis.cz/cs)
* [Czech Republic | **en**](https://www.novartis.cz/en)
* [Denmark | **da**](https://www.novartis.dk/)
* [Egypt | **en**](https://www.novartis.com.eg/)
* [Estonia | **et**](https://www.novartis.ee/)
* [Finland | **fi**](https://www.novartis.fi/)
* [France | **fr**](https://www.novartis.fr/)
* [Germany | **de**](https://www.novartis.de/)
* [Greece | **el**](https://www.novartis.gr/)
* [Hong Kong S.A.R. | **zh**](https://www.novartis.com.hk/)
* [Hungary | **hu**](https://www.novartis.hu/)
* [India | **en**](https://www.novartis.in/)
* [Indonesia | **en**](https://www.id.novartis.com/)
* [Ireland | **en**](https://www.novartis.ie/)
* [Israel | **he**](https://www.novartis.co.il/)
* [Italy | **it**](https://www.novartis.it/)
* [Japan | **ja**](https://www.novartis.co.jp/)
* [Korea | **ko**](https://www.novartis.co.kr/)
* [Latvia | **lv**](https://www.novartis.lv/)
* [Lithuania | **lt**](https://www.novartis.lt/)
* [Mainland China | **zh**](https://www.novartis.com.cn/)
* [Malaysia | **en**](https://www.novartis.com/my-en)
* [Mexico | **es**](https://www.novartis.com.mx/)
* [Netherlands | **nl**](https://www.novartis.nl/)
* [Norway | **no**](https://www.novartis.no/)
* [Global | **en**](https://www.novartis.com/)
* [Sandoz | **en**](https://www.sandoz.com)
* [Novartis Foundation | **en**](https://www.novartisfoundation.org)
* [Pakistan | **en**](https://www.novartis.com/pk-en)
* [Philippines | **en**](https://www.novartis.com/ph-en/)
* [Poland | **pl**](https://www.novartis.pl/)
* [Portugal | **pt**](https://www.novartis.pt/)
* [Romania | **ro**](https://www.novartis.com.ro/)
* [Russia | **ru**](https://www.novartis.ru/)
* [Serbia | **sr**](https://www.novartis.rs/)
* [Singapore | **en**](https://www.novartis.com.sg/)
* [Slovakia | **sk**](https://www.novartis.sk/)
* [South Africa | **en**](https://www.novartis.co.za/)
* [Spain | **es**](https://www.novartis.es/)
* [Sweden | **sv**](https://www.novartis.se/)
* [Switzerland | **de**](https://www.novartis.ch/de/)
* [Switzerland | **fr**](https://www.novartis.ch/fr/)
* [Taiwan | **zh**](https://www.novartis.com.tw/)
* [Turkey | **tr**](https://www.novartis.com.tr/)
* [United Kingdom | **en**](https://www.novartis.co.uk/)
* [United States | **en**](https://www.novartis.us/)
* [Venezuela | **es**](https://www.novartis.com.ve/)
* Menu
	+ [About](/about)
	
	
	
	
	
	
		- [Board of Directors](/about/board-directors)
		
		
		
		
		
		
			* [Joerg Reinhardt](/about/board-directors/joerg-reinhardt)
			* [Simon Moroney](/about/board-directors/simon-moroney)
			* [Nancy C. Andrews](/about/board-directors/nancy-c-andrews)
			* [Ton Buechner](/about/board-directors/ton-buechner)
			* [Patrice Bula](/about/board-directors/patrice-bula)
			* [Elizabeth (Liz) Doherty](/about/board-directors/elizabeth-liz-doherty)
			* [Ana de Pro Gonzalo](/about/board-directors/ana-de-pro-gonzalo)
			* [Bridgette Heller](/about/board-directors/bridgette-heller)
			* [Daniel Hochstrasser](/about/board-directors/daniel-hochstrasser)
			* [Frans van Houten](/about/board-directors/frans-van-houten)
			* [Charles L. Sawyers](/about/board-directors/charles-l-sawyers)
			* [William T. Winters](/about/board-directors/william-t-winters)
			* [John D. Young](/about/board-directors/john-d-young)
			* [Charlotte Pamer-Wieser](/about/board-directors/charlotte-pamer-wieser)
		- [Executive Committee](/about/executive-committee)
		
		
		
		
		
		
			* [Vasant (Vas) Narasimhan](/about/executive-committee/vasant-narasimhan)
			* [Shreeram Aradhye](/about/executive-committee/shreeram-aradhye)
			* [Victor Bulto](/about/executive-committee/victor-bulto)
			* [Aharon (Ronny) Gal](/about/executive-committee/aharon-ronny-gal-phd)
			* [Karen L. Hale](/about/executive-committee/karen-hale)
			* [Harry Kirsch](/about/executive-committee/harry-kirsch)
			* [Rob Kowalski](/about/executive-committee/rob-kowalski)
			* [Steffen Lang](/about/executive-committee/steffen-lang)
			* [Fiona Marshall](/about/executive-committee/fiona-marshall)
			* [Klaus Moosmayer](/about/executive-committee/klaus-moosmayer)
			* [Marie-France Tschudin](/about/executive-committee/marie-france-tschudin)
			* [Lutz Hegemann](/about/executive-committee/lutz-hegemann)
			* [Kees Roks](/about/executive-committee/kees-roks)
			* [Richard Saynor](/about/executive-committee/richard-saynor)
			* [Michael Willi](/about/executive-committee/michael-willi)
		- [Strategy](/about/strategy)
		
		
		
		
		
		
			* [People and Culture](/about/strategy/people-and-culture)
			* [Data and Digital](/about/strategy/data-and-digital)
		- [Products](/about/products)
		- [Innovative Medicines](/about/innovative-medicines)
		- [Sandoz](https://www.sandoz.com/)
		- [Diversity, Equity & Inclusion](/about/diversity-equity-inclusion)
		
		
		
		
		
		
			* [Equity](/about/diversity-equity-inclusion/equity)
			* [Diversity, Equity & Inclusion Governance and Community](/about/diversity-equity-inclusion/diversity-equity-inclusion-governance-and-community)
			* [Inclusivity](/about/diversity-equity-inclusion/inclusivity)
			* [Parental Leave](/about/diversity-equity-inclusion/parental-leave)
			* [Society](/about/diversity-equity-inclusion/society)
		- [Manufacturing](/about/manufacturing)
		- [Quality](/about/quality)
		
		
		
		
		
		
			* [Audit program](/about/quality/audit-program)
			* [Novartis Quality Management System (QMS)](/about/quality/novartis-quality-management-system-qms)
			* [Product and patient safety training](/about/quality/product-and-patient-safety-training)
			* [Regulatory inspections](/about/quality/regulatory-inspections)
			* [Product recalls](/about/quality/product-recalls)
			* [Third-party suppliers](/about/quality/third-party-suppliers)
		- [Awards and Recognition](/about/awards-and-recognition)
	
	
	
	
	[![Male scientist in lab](/sites/novartis_com/files/styles/image_mega_menu/public/2021-10/male-scientist-lab-about-hero.jpg.webp?itok=Z7cNyUur "Male scientist in lab")](/about-novartis)
	[About Novartis](/about-novartis)
	+ [Patients and Caregivers](/patients-and-caregivers)
	
	
	
	
	
	
		- [Novartis Commitment to Patients and Caregivers](/patients-and-caregivers/novartis-commitment-patients-and-caregivers)
		- [Diseases](/diseases)
		- [Patient Organization Funding](/esg/reporting/transparency-and-disclosure/patient-organization-funding)
		- [Stories: Patients Perspectives](/news/stories/patient-perspectives)
	
	
	
	
	[![Couple holding hands](/sites/novartis_com/files/styles/image_mega_menu/public/2021-10/couple-holding-hands-cropped.jpg.webp?itok=EcaZ9s8W "Couple holding hands")](/patients-and-caregivers)
	[Patients & Caregivers](/patients-and-caregivers)
	+ [Healthcare Professionals](/healthcare-professionals)
	
	
	
	
	
	
		- [Medical Congresses and Events](/healthcare-professionals/medical-congresses-and-events)
		
		
		
		
		
		
			* [Abstract summaries for EULAR](/healthcare-professionals/medical-congresses-and-events/abstract-summaries-eular)
			* [Abstract summaries for ACR](/healthcare-professionals/medical-congresses-and-events/abstract-summaries-acr)
		- [Products](/about/products)
		- [Novartis Pipeline](/research-development/novartis-pipeline)
		- [Managed Access Programs](/healthcare-professionals/managed-access-programs)
		
		
		
		
		
		
			* [Novartis Gene Therapies Managed Access Program](/healthcare-professionals/managed-access-programs/novartis-gene-therapies-managed-access-program)
		- [Novartis External Funding](/healthcare-professionals/novartis-external-funding)
		- [Healthcare Professional Resources by Country](/healthcare-professionals/healthcare-professional-resources-country)
		- [Investigator-Initiated Trials / Studies](/healthcare-professionals/investigator-initiated-trials-studies)
		- [Transparency and Disclosure](/esg/reporting/transparency-and-disclosure)
		- [Novartis Medical Information](/healthcare-professionals/novartis-medical-information)
		
		
		
		
		
		
			* [Submit medical enquiry](/healthcare-professionals/novartis-medical-information/submit-medical-enquiry)
	
	
	
	
	[![Doctor](/sites/novartis_com/files/styles/image_mega_menu/public/2021-10/hcp-landing-page-hero.jpg.webp?itok=bKOlsHBz "Doctor")](/healthcare-professionals)
	[Healthcare Professionals](/healthcare-professionals)
	+ [Research & Development](/research-development)
	
	
	
	
	
	
		- [Novartis Institutes for BioMedical Research](/research-development/novartis-institutes-biomedical-research)
		
		
		
		
		
		
			* [Collaborations](/research-development/novartis-institutes-biomedical-research/collaborations)
			* [NIBR Global Scholars Program](/research-development/novartis-institutes-biomedical-research/nibr-global-scholars-program)
		- [Technology Platforms](/research-development/technology-platforms)
		
		
		
		
		
		
			* [Radioligand Therapy](/research-development/technology-platforms/radioligand-therapy)
			* [Gene Therapy](/research-development/technology-platforms/gene-therapy)
			* [Cell Therapy](/research-development/technology-platforms/cell-therapy)
		- [Research Disease Areas](/research-development/research-disease-areas)
		
		
		
		
		
		
			* [Immuno-oncology research at Novartis](/research-development/research-disease-areas/immuno-oncology-research-novartis)
			* [Oncology research at Novartis](/research-development/research-disease-areas/oncology-research-novartis)
			* [Cardiovascular and metabolic disease research at Novartis](/research-development/research-disease-areas/cardiovascular-and-metabolic-disease-research-novartis)
			* [Autoimmunity, transplantation and inflammatory disease research at Novartis](/research-development/research-disease-areas/autoimmunity-transplantation-and-inflammatory-disease-research-novartis)
			* [Ophthalmology research at Novartis](/research-development/research-disease-areas/ophthalmology-research-novartis)
			* [Neuroscience Research at Novartis](/research-development/research-disease-areas/neuroscience-research-novartis)
			* [Musculoskeletal Disease Research at Novartis](/research-development/research-disease-areas/musculoskeletal-disease-research-novartis)
			* [DAx: exploratory disease research at Novartis](/research-development/research-disease-areas/dax-exploratory-disease-research-novartis)
		- [Research Locations](/research-development/research-locations)
		
		
		
		
		
		
			* [Novartis Institute for Tropical Diseases](/research-development/research-locations/novartis-institute-tropical-diseases)
		- [Novartis Pipeline](/research-development/novartis-pipeline)
		- [Translational Medicine](/research-development/translational-medicine-research-novartis)
		- [Research & Development Approach](/research-development/research-development-approach)
		- [Research Collaborations](/research-development/research-collaborations)
		- [Open Source Science](/research-development/open-source-science)
		- [Stories from our Labs](/news/stories/from-our-labs)
	
	
	
	
	[![Scientists conducting innovative research experiments](/sites/novartis_com/files/styles/image_mega_menu/public/2021-09/novartis-innovative-medicines-hero.jpg.webp?itok=amhQHdOD "Scientists conducting innovative research experiments")](/research-development)
	[Research & Development](/research-development)
	+ [ESG](/esg)
	
	
	
	
	
	
		- [Access](/esg/access)
		
		
		
		
		
		
			* [Creating sustainable business models](/esg/access/creating-sustainable-business-models)
			* [Value-Based Pricing](/esg/access/value-based-pricing)
			* [Sub-Saharan Africa](/esg/access/sub-saharan-africa)
			* [Donations](/esg/access/donations)
			* [Novartis Access Principles](/esg/access/novartis-access-principles)
			* [Novartis Oncology Access](/esg/access/novartis-oncology-access)
			* [Patents and Licensing](/esg/access/patents-and-licensing)
		- [Ethics, Risk and Compliance](/esg/ethics-risk-and-compliance)
		
		
		
		
		
		
			* [Ethical Behavior](/esg/ethics-risk-and-compliance/ethical-behavior)
			* [Compliance](/esg/ethics-risk-and-compliance/compliance)
			* [Human Rights](/esg/ethics-risk-and-compliance/human-rights)
			* [Learning and Engagement](/esg/ethics-risk-and-compliance/learning-and-engagement)
			* [Risk management](/esg/ethics-risk-and-compliance/risk-management)
		- [Environmental Sustainability](/esg/environmental-sustainability)
		
		
		
		
		
		
			* [Climate](/esg/environmental-sustainability/climate)
			* [Waste](/esg/environmental-sustainability/waste)
			* [Water](/esg/environmental-sustainability/water)
		- [Global Health](/esg/global-health)
		
		
		
		
		
		
			* [Anti-Microbial Resistance (AMR)](/esg/global-health/anti-microbial-resistance-amr)
			* [Avoidable Blindness](/esg/global-health/avoidable-blindness)
			* [Chagas Disease](/diseases/chagas-disease)
			* [Leprosy](/diseases/leprosy)
			* [Malaria](/diseases/malaria)
			* [Sickle Cell Disease (SCD)](/diseases/sickle-cell-disease)
			* [Novartis Foundation](https://www.novartisfoundation.org/)
		- [Diversity, Equity & Inclusion](/about/diversity-equity-inclusion)
		- [Reporting](/esg/reporting)
		
		
		
		
		
		
			* [ESG Rating Performance](/esg/reporting/esg-rating-performance)
			* [Codes, Policies and Guidelines](/esg/reporting/codes-policies-and-guidelines)
			* [Materiality Assessment](/esg/reporting/materiality-assessment)
			* [Transparency and Disclosure](/esg/reporting/transparency-and-disclosure)
			* [Targets](/esg/reporting/targets)
			* [Positions](/esg/reporting/positions)
		- [ESG Index](/esg/index)
	
	
	
	
	[![Young patients waiting outside an hospital in Rwanda](/sites/novartis_com/files/styles/image_mega_menu/public/2021-10/young-patients-waiting-outside-hospital-in-rwanda.jpg.webp?itok=CIRSKQ-O "Young patients waiting outside an hospital in Rwanda")](/environmental-social-and-governance)
	[Environmental, Social and Governance](/environmental-social-and-governance)
	+ [Investors](/investors)
	
	
	
	
	
	
		- [Event Calendar](/investors/event-calendar)
		- [Financial Data](/investors/financial-data)
		
		
		
		
		
		
			* [Novartis Annual Results](/investors/financial-data/annual-results)
			* [Novartis Quarterly Results](/investors/financial-data/quarterly-results)
			* [Novartis SEC Filings](/investors/financial-data/sec-filings)
			* [Product Sales](/investors/financial-data/product-sales)
			* [Fixed-Income Securities](/investors/financial-data/fixed-income-securities)
			* [Expected Currency Impact](/investors/financial-data/expected-currency-impact)
		- [Share Data & Analysis](/investors/share-data-analysis)
		
		
		
		
		
		
			* [Share Monitor](/investors/share-data-analysis/share-monitor)
			* [Dividend Information](/investors/share-data-analysis/dividend-information)
			* [Share Ownership](/investors/share-data-analysis/share-ownership)
			* [Share Overview](/investors/share-data-analysis/share-overview)
			* [Return On Investment Calculator](/investors/share-data-analysis/return-investment-calculator)
		- [Shareholder Information](/investors/shareholder-information)
		
		
		
		
		
		
			* [General Meetings](/investors/shareholder-information/general-meetings)
			* [American Depository Receipts (ADR)](/investors/shareholder-information/american-depository-receipts-adr)
			* [Share Buy-Back](/investors/shareholder-information/share-buy-back)
			* [Frequently Asked Questions](/investors/shareholder-information/frequently-asked-questions)
		- [Company Overview](/investors/company-overview)
		
		
		
		
		
		
			* [Corporate Governance](/investors/company-overview/corporate-governance)
		- [Novartis Annual Reporting Suite](/investors/novartis-annual-reporting-suite)
		
		
		
		
		
		
			* [Reporting Archive](/investors/novartis-annual-reporting-suite/reporting-archive)
			* [Publications Order Form](/news/stay-up-to-date)
		- [ESG](/esg)
	
	
	
	
	[![Hands marking a test tube](/sites/novartis_com/files/styles/image_mega_menu/public/2021-09/investors-hands-marking-image-2x.jpg.webp?itok=amZeBpad "Hands marking a test tube")](/investors)
	[Investors](/investors)
	+ [News](/news)
	
	
	
	
	
	
		- [News Archive](/news/news-archive)
		- [Media Library](/news/media-library)
		- [Stories](/stories)
		- [Subscribe](/news/stay-up-to-date)
	
	
	
	
	[![People at the table with screens](/sites/novartis_com/files/styles/image_mega_menu/public/2021-10/news-hero.jpg.webp?itok=_KWeBjM5 "People at the table with screens")](/news)
	[News](/news)
	+ [Careers](/careers)
	
	
	
	
	
	
		- [Career Search](/careers/career-search)
		- [Our Teams](/careers/our-teams)
		
		
		
		
		
		
			* [Careers in Commercial](/careers/our-teams/careers-commercial)
			* [Careers in Communications and Engagement](/careers/our-teams/careers-communications-and-engagement)
			* [Careers in Consulting](/careers/our-teams/careers-consulting)
			* [Careers in Digital](/careers/our-teams/careers-digital)
			* [Careers in Health, Safety & Environment](/careers/our-teams/careers-health-safety-environment)
			* [Careers in Information Technology (IT)](/careers/our-teams/careers-information-technology-it)
			* [Careers in Medical & Development](/careers/our-teams/careers-medical-development)
			* [Careers in People & Organization](/careers/our-teams/careers-people-organization)
			* [Careers in Procurement](/careers/our-teams/careers-procurement)
			* [Careers in Research](/careers/our-teams/careers-research)
			* [Careers in Strategy](/careers/our-teams/careers-strategy)
			* [Careers in Manufacturing and Supply](/careers/our-teams/careers-manufacturing-supply)
			* [Ethics, Risk & Compliance (ERC)](/careers/our-teams/ethics-risk-compliance-erc)
			* [Careers in Legal](/careers/our-teams/careers-legal)
		- [Career Programs](/careers/career-programs)
		
		
		
		
		
		
			* [Community Exploration & Learning Lab (CELL)](/careers/career-programs/community-exploration-learning-lab-cell)
			* [Postdoc Program](/careers/career-programs/postdoc-program)
		- [Early Talent](/careers/early-talent)
		
		
		
		
		
		
			* [US NIBR Internship Programs](/careers/early-talent/us-nibr-internship-programs)
		- [International Careers](/careers/international-careers)
		- [Personal Growth](/careers/personal-growth)
		- [Well-being](/careers/well-being)
	
	
	
	
	[![A female Novartis researcher](/sites/novartis_com/files/styles/image_mega_menu/public/2021-07/join-us-hero-image.jpg.webp?itok=L8tV4Jr_ "Novartis researcher")](/careers)
	[Careers](/careers)
	+ [Clinical Trials](/clinicaltrials)
	
	
	
	
	
	
	
	
	
	[![doctor taking the blood pressure of her patient](/sites/novartis_com/files/styles/image_mega_menu/public/2021-10/patient-and-doctor-clinicaltrials.png.webp?itok=ZloZGYDw "doctor taking the blood pressure of her patient")](/clinicaltrials)
	[Clinical Trials](/clinicaltrials)
	+ [Partnering](/partnering)
	
	
	
	
	
	
	
	
	
	[![Business people working in a dark room](/sites/novartis_com/files/styles/image_mega_menu/public/2021-09/business-people-meeting-room-at-night.jpg.webp?itok=CxzLsWKV "Business people working in a dark room")](/partnering)
	[Partnering](/partnering)
	+ [Supplier Portal](/supplier-portal)
	
	
	
	
	
	
	
	
	
	[![Group of business people in a meeting area](/sites/novartis_com/files/styles/image_mega_menu/public/2022-07/suppliers-procurement-business-environment.jpg.webp?itok=Lp2pit_P "Group of business people in a meeting area")](/supplier-portal)
	[Supplier Portal](/supplier-portal)
	+ [Report side effects](/report)
	+ [Contacts](/contacts)
	
	
	
	
	
	
	
	
	
	[![Office Cubicle](/sites/novartis_com/files/styles/image_mega_menu/public/2021-10/contacts.jpg.webp?itok=F2lR0Pth "Office Cubicle")](/contacts)
	[Contacts](/contacts)
[![Group of scientists working in a lab in winter](/sites/novartis_com/files/styles/image_mega_menu/public/2022-02/scientists-working-lab-homepage.jpg.webp?itok=DLA2B06p "Scientists working in a lab")](/home)
[Home](/home)
Header
 
![Dr. Payal Laad (center) of Novartis poses for a photograph with two community health leaders after speaking at a Arogya Parivar health camp in India](/sites/novartis_com/files/styles/banner_image_1920/public/2023-03/dr-payal-laad-with-two-community-health-leaders.jpg.webp?itok=ERoNmpOB "Dr. Payal Laad (center) of Novartis poses for a photograph with two community health leaders after speaking at a Arogya Parivar health camp in India")
# 
At Novartis, we are reimagining medicine
[Previous](#paragraph--2146)
[Next](#paragraph--2146)
 
[![Male scientist in lab](/sites/novartis_com/files/styles/cards_1_3/public/2021-10/male-scientist-lab-about-hero.jpg.webp?itok=59901eRO "Male scientist in lab")
### 
About Novartis
We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.](/about)
[![Doctor in Rwanda weighing a baby](/sites/novartis_com/files/styles/cards_1_3/public/2023-01/doctor-weighing-baby-rwanda.jpg.webp?itok=cQkxbUIA "Doctor in Rwanda weighing a baby")
### 
Access
We are committed to bringing more of our medicines to more people, no matter where they are.](/esg/access)
[![Four colleagues sitting around a table at the office](/sites/novartis_com/files/styles/cards_1_3/public/2022-02/colleagues-in-office-people-and-culture.jpg.webp?itok=b1cFU1Zn "Colleagues in the office")
### 
People and Culture
Novartis is building an Inspired, Curious and Unbossed culture.](/about/strategy/people-and-culture)
## 
Latest news
[Mar 17, 2023
* Media Release
###  Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer](/news/media-releases/novartis-tafinlar-mekinist-approved-fda-pediatric-patients-braf-v600e-low-grade-glioma-most-common-pediatric-brain-cancer)
[Mar 09, 2023
* Media Release
###  Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines](/news/media-releases/sandoz-signs-memorandum-understanding-build-new-biologics-production-plant-slovenia-support-increasing-global-demand-biosimilar-medicines)
[Mar 07, 2023
* Media Release
###  Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting](/news/media-releases/novartis-shareholders-approve-all-resolutions-proposed-board-directors-annual-general-meeting-6)
[All news](/news/news-archive "All news")
[![Production specialist safely holding materials](/sites/novartis_com/files/styles/cards_50_50/public/2023-01/production-specialist-safely-holding-materials-half-card.jpg.webp?itok=EwGiVxXf "Production specialist safely holding materials")
### 
Novartis 2022 Financial Results
Novartis announced the company’s fourth quarter and 2022 full year financial results.](/news/novartis-2022-financial-results)
[![Sandoz logo white on blue](/sites/novartis_com/files/styles/cards_50_50/public/2023-01/sandoz-logo-white-half-card.jpg.webp?itok=fVq3Wbza "Sandoz logo white on blue")
### 
Sandoz spin-off
Novartis has announced an intention to separate the Sandoz business to create a standalone company by way of a 100% spin-off.](/news/sandoz-spinoff)
 
![Van Lacour, prostate cancer patient living in Natchez, Louisiana, who received a Novartis radioligand therapy](/sites/novartis_com/files/styles/banner_image_1920/public/2023-01/novartis-in-society-2022-banner.jpg.webp?itok=Hhw54wDI "Van Lacour, prostate cancer patient living in Natchez, Louisiana, who received a Novartis radioligand therapy")
# 
[Novartis in Society Integrated Report 2022](https://www.reporting.novartis.com/2022/novartis-in-society.html "Novartis in Society Integrated Report 2022")
In 2022, we continued to reimagine medicine and deliver on our purpose to improve and extend people's lives.
[Learn more](https://www.reporting.novartis.com/2022/novartis-in-society.html "Learn more")
[Previous](#paragraph--95946)
[Next](#paragraph--95946)
![Infant patient being held by a healthcare professional during examination ](/sites/novartis_com/files/styles/cta_image/public/2022-12/compassionate-use-heroimage1.png.webp?itok=XfDkBRQ9 "Infant patient being held by a healthcare professional during examination")
## 
Compassionate use: Providing access to much needed treatments
 What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.
[Read more](/stories/compassionate-use-providing-access-much-needed-treatments "Read more")
[![Young patients waiting outside an hospital in Rwanda](/sites/novartis_com/files/styles/cards_50_50/public/2021-10/young-patients-waiting-outside-hospital-in-rwanda.jpg.webp?itok=N7J7upT3 "Young patients waiting outside an hospital in Rwanda")
### 
Environmental, Social and Governance
We have a responsibility and opportunity to lead the world in creating a positive social change, embracing societal impact as a core business objective.](/esg)
[![Pediatrician talking with young teenage girl](/sites/novartis_com/files/styles/cards_50_50/public/2023-01/pediatrician-talking-with-young-teenage-girl-in-office.jpg.webp?itok=tmu_jpHw "Pediatrician talking with young teenage girl")
### 
The Novartis Commitment to Patients and Caregivers
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives.](/patients-and-caregivers/novartis-commitment-patients-and-caregivers)
## Novartis
###### Navigate Novartis
Navigate Novartis
* [Patients and Caregivers](/patients-and-caregivers)
* [Healthcare Professionals](/healthcare-professionals)
* [Researchers](/research-development)
* [Job Seekers](/careers)
* [Journalists](/news)
* [Investors](/investors)
* [Partners](/partnering)
* [Suppliers](/supplier-portal)
###### Topics
Topics
* [Clinical Trials](/clinicaltrials)
* [ESG](/esg)
###### Explore
Explore
* [Stories](/stories)
* [Diseases](/diseases)
* [Locations](/about/locations)
* [Products](/about/products)
* [Novartis Pipeline](/research-development/novartis-pipeline)
###### Novartis companies
Novartis companies
* [Sandoz](https://www.sandoz.com)
* [Advanced Accelerator Applications](https://www.adacap.com/)
* [Gyroscope Therapeutics](https://www.gyroscopetx.com/)
* 
* 
* 
* 
* 
###### Footer Bottom
Footer Bottom
 © 2023 Novartis AG
* [Terms of Use](/terms-use)
* [Privacy](/privacy)
* [Contacts](/contacts)
* [Cookie Settings](#cookie-settings-button)
* [Site Map](/sitemap.xml)
* [Web Accessibility](/accessibility)
* [Open Source](/open-source)
[Novartis Site Directory](/novartis-directory "Novartis Site Directory")
This site is intended for a global audience
